Identification

Name
Bazedoxifene
Accession Number
DB06401
Type
Small Molecule
Groups
Approved, Investigational
Description

Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the European Union (marketed in Italy and Spain) and Japan, and is in the late phases of review by the United States' Food and Drug Administration (FDA). Bazedoxifene is yet to be approved by the FDA.

Structure
Thumb
Synonyms
  • bazedoxifene/conjugated estrogens
External IDs
TSE-424 / UNII-J70472UD3D / UNII-Q16TT9C5BK / WAY-140424 / WAY-TSE-424
Product Ingredients
IngredientUNIICASInChI Key
Bazedoxifene acetateJ70472UD3D198481-33-3OMZAMQFQZMUNTP-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DuaveeBazedoxifene acetate (20 mg/1) + Conjugated estrogens (.45 mg/1)Tablet, film coatedOralU.S. Pharmaceuticals2013-11-15Not applicableUs
DuaveeBazedoxifene acetate (20 mg/1) + Conjugated estrogens (.45 mg/1)Tablet, film coatedOralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2013-10-03Not applicableUs
DuaveeBazedoxifene acetate (20 mg/1) + Conjugated estrogens (.45 mg/1)Tablet, film coatedOralU.S. Pharmaceuticals2013-11-15Not applicableUs
DuaviveBazedoxifene (20 mg) + Conjugated estrogens (0.45 mg)Tablet, multilayer, extended releaseOralPfizer2014-12-16Not applicableEu
DuaviveBazedoxifene (20 mg) + Conjugated estrogens (0.45 mg)Tablet, multilayer, extended releaseOralPfizer2016-12-20Not applicableCanada
International/Other Brands
Aprela / Viviant
Categories
UNII
Q16TT9C5BK
CAS number
198481-32-2
Weight
Average: 470.613
Monoisotopic: 470.256942963
Chemical Formula
C30H34N2O3
InChI Key
UCJGJABZCDBEDK-UHFFFAOYSA-N
InChI
InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3
IUPAC Name
1-({4-[2-(azepan-1-yl)ethoxy]phenyl}methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol
SMILES
CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1

Pharmacology

Indication

Investigated for use/treatment in osteoporosis and menopause.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Bazedoxifene belongs to a class of compounds known as selective estrogen receptor modulators (SERMs). Bazedoxifene acts as both an oestrogen-receptor agonist and/or antagonist, depending upon the cell and tissue type and target genes. Bazedoxifene decreases bone resorption and reduces biochemical markers of bone turnover to the premenopausal range. These effects on bone remodelling lead to an increase in bone mineral density (BMD), which in turn contributes to a reduction in the risk of fractures. Bazedoxifene functions primarily as an oestrogen-receptor antagonist in uterine and breast tissues.

TargetActionsOrganism
AEstrogen receptor alpha
antagonist
agonist
Human
UEstrogen receptor betaNot AvailableHuman
Absorption

Bazedoxifene is rapidly absorbed with a tmax of approximately 2 hours and exhibits a linear increase in plasma concentrations for single doses from 0.5 mg up to 120 mg and multiple daily doses from 1 mg to 80 mg. The absolute bioavailability of bazedoxifene is approximately 6%.

Volume of distribution

Following intravenous administration of a 3 mg dose of bazedoxifene, the volume of distribution is 14.7 ± 3.9 l/kg.

Protein binding

98-99%.

Metabolism

Glucuronidation is the major metabolic pathway. After peroral application, bazedoxifene is metabolized by UDP-glucuronosyltransferases (UGTs) to bazedoxifene-4'-glucuronide (M4) and bazedoxifene-5-glucuronide (M5).Little or no cytochrome P450-mediated metabolism is evident. The concentrations of this glucuronide are approximately 10-fold higher than those of unchanged active substance in plasma.

Route of elimination

The major route of elimination of radio-labelled bazedoxifene is the faeces, and less than 1% of the dose is eliminated in urine.

Half life

~30 hours.

Clearance

The apparent oral clearance of bazedoxifene is approximately 4 to 5 l/h/kg.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Bazedoxifene.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Bazedoxifene.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Bazedoxifene.Experimental, Illicit
AbciximabBazedoxifene may decrease the anticoagulant activities of Abciximab.Approved
AceclofenacAceclofenac may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
AcenocoumarolBazedoxifene may decrease the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenAcetaminophen may increase the thrombogenic activities of Bazedoxifene.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the thrombogenic activities of Bazedoxifene.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Bazedoxifene.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Bazedoxifene.Experimental, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Bazedoxifene.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Bazedoxifene.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Bazedoxifene.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the thrombogenic activities of Bazedoxifene.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Bazedoxifene.Approved, Investigational
AncrodBazedoxifene may decrease the anticoagulant activities of Ancrod.Approved, Investigational
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Bazedoxifene.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Bazedoxifene.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Bazedoxifene.Investigational
Anthrax immune globulin humanBazedoxifene may increase the thrombogenic activities of Anthrax immune globulin human.Approved
AntipyrineAntipyrine may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
Antithrombin III humanBazedoxifene may decrease the anticoagulant activities of Antithrombin III human.Approved
AntrafenineAntrafenine may increase the thrombogenic activities of Bazedoxifene.Approved
ApixabanBazedoxifene may decrease the anticoagulant activities of Apixaban.Approved
ArdeparinBazedoxifene may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanBazedoxifene may decrease the anticoagulant activities of Argatroban.Approved, Investigational
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Bazedoxifene.Investigational
BalsalazideBalsalazide may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminBazedoxifene may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Bazedoxifene.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Bazedoxifene.Approved, Vet Approved
BivalirudinBazedoxifene may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BromfenacBromfenac may increase the thrombogenic activities of Bazedoxifene.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Bazedoxifene.Approved
BufexamacBufexamac may increase the thrombogenic activities of Bazedoxifene.Approved, Experimental
Capromab pendetideBazedoxifene may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CapsaicinCapsaicin may increase the thrombogenic activities of Bazedoxifene.Approved
CarbamazepineThe serum concentration of Bazedoxifene can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenCarprofen may increase the thrombogenic activities of Bazedoxifene.Approved, Vet Approved, Withdrawn
CelecoxibCelecoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
CertoparinBazedoxifene may decrease the anticoagulant activities of Certoparin.Approved, Investigational
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Bazedoxifene.Approved
ChlorphenesinChlorphenesin may increase the thrombogenic activities of Bazedoxifene.Approved, Vet Approved, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the thrombogenic activities of Bazedoxifene.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Bazedoxifene.Approved, Investigational
CimicoxibCimicoxib may increase the thrombogenic activities of Bazedoxifene.Investigational
CisplatinCisplatin may increase the thrombogenic activities of Bazedoxifene.Approved
Citric AcidBazedoxifene may decrease the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Bazedoxifene.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Bazedoxifene.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Bazedoxifene.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Bazedoxifene.Approved
Clodronic AcidClodronic Acid may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational, Vet Approved
Conestat alfaBazedoxifene may increase the thrombogenic activities of Conestat alfa.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Bazedoxifene.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Bazedoxifene.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Bazedoxifene.Approved, Investigational
Dabigatran etexilateBazedoxifene may decrease the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinBazedoxifene may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidBazedoxifene may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanBazedoxifene may decrease the anticoagulant activities of Darexaban.Investigational
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Bazedoxifene.Approved, Investigational
DesirudinBazedoxifene may decrease the anticoagulant activities of Desirudin.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Bazedoxifene.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Bazedoxifene.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Bazedoxifene.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Bazedoxifene.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Bazedoxifene.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Bazedoxifene.Vet Approved
DexibuprofenDexibuprofen may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
DexketoprofenDexketoprofen may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
DextranBazedoxifene may decrease the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacDiclofenac may increase the thrombogenic activities of Bazedoxifene.Approved, Vet Approved
DicoumarolBazedoxifene may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Bazedoxifene.Approved
DiflunisalDiflunisal may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Bazedoxifene.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Bazedoxifene.Approved
DrospirenoneDrospirenone may increase the thrombogenic activities of Bazedoxifene.Approved
DroxicamDroxicam may increase the thrombogenic activities of Bazedoxifene.Withdrawn
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Bazedoxifene.Approved
Edetic AcidBazedoxifene may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBazedoxifene may decrease the anticoagulant activities of Edoxaban.Approved
EnoxaparinBazedoxifene may decrease the anticoagulant activities of Enoxaparin.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Bazedoxifene.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Bazedoxifene.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Bazedoxifene.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Bazedoxifene.Approved
EtanerceptEtanercept may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
Ethyl biscoumacetateBazedoxifene may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational, Vet Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Bazedoxifene.Approved, Investigational
FenoprofenFenoprofen may increase the thrombogenic activities of Bazedoxifene.Approved
Ferulic acidBazedoxifene may decrease the anticoagulant activities of Ferulic acid.Experimental
Fish oilFish oil may increase the thrombogenic activities of Bazedoxifene.Approved, Nutraceutical
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Bazedoxifene.Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Bazedoxifene.Approved, Investigational
FluindioneBazedoxifene may decrease the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Bazedoxifene.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Bazedoxifene.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Bazedoxifene.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Bazedoxifene.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Bazedoxifene.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Bazedoxifene.Approved, Investigational
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Bazedoxifene.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Bazedoxifene.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Bazedoxifene.Approved
FlurbiprofenFlurbiprofen may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Bazedoxifene.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Bazedoxifene.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Bazedoxifene.Approved
FondaparinuxBazedoxifene may decrease the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumBazedoxifene may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Bazedoxifene.Approved, Investigational, Withdrawn
FosphenytoinThe serum concentration of Bazedoxifene can be decreased when it is combined with Fosphenytoin.Approved, Investigational
GabexateBazedoxifene may decrease the anticoagulant activities of Gabexate.Investigational
GinsengGinseng may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational, Nutraceutical
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Bazedoxifene.Approved, Investigational, Withdrawn
HE3286The serum concentration of HE3286 can be increased when it is combined with Bazedoxifene.Investigational
HeparinBazedoxifene may decrease the anticoagulant activities of Heparin.Approved, Investigational
Human C1-esterase inhibitorBazedoxifene may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Bazedoxifene.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Bazedoxifene.Approved, Vet Approved
IbuprofenIbuprofen may increase the thrombogenic activities of Bazedoxifene.Approved
IcosapentIcosapent may increase the thrombogenic activities of Bazedoxifene.Approved, Nutraceutical
IdraparinuxBazedoxifene may decrease the anticoagulant activities of Idraparinux.Investigational
IndomethacinIndomethacin may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Bazedoxifene.Investigational
KetoprofenKetoprofen may increase the thrombogenic activities of Bazedoxifene.Approved, Vet Approved
KetorolacKetorolac may increase the thrombogenic activities of Bazedoxifene.Approved
LenalidomideBazedoxifene may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinBazedoxifene may decrease the anticoagulant activities of Lepirudin.Approved
LetaxabanBazedoxifene may decrease the anticoagulant activities of Letaxaban.Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Bazedoxifene.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Bazedoxifene.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Bazedoxifene.Approved
LornoxicamLornoxicam may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Bazedoxifene.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the thrombogenic activities of Bazedoxifene.Approved
ME-609The serum concentration of ME-609 can be increased when it is combined with Bazedoxifene.Investigational
Meclofenamic acidMeclofenamic acid may increase the thrombogenic activities of Bazedoxifene.Approved, Vet Approved
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Bazedoxifene.Approved
Mefenamic acidMefenamic acid may increase the thrombogenic activities of Bazedoxifene.Approved
MelagatranBazedoxifene may decrease the anticoagulant activities of Melagatran.Experimental
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Bazedoxifene.Vet Approved
MeloxicamMeloxicam may increase the thrombogenic activities of Bazedoxifene.Approved, Vet Approved
MesalazineMesalazine may increase the thrombogenic activities of Bazedoxifene.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Bazedoxifene.Approved, Vet Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Bazedoxifene.Approved, Vet Approved
MorniflumateMorniflumate may increase the thrombogenic activities of Bazedoxifene.Approved
NabumetoneNabumetone may increase the thrombogenic activities of Bazedoxifene.Approved
NadroparinBazedoxifene may decrease the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatBazedoxifene may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
NaproxenNaproxen may increase the thrombogenic activities of Bazedoxifene.Approved, Vet Approved
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Bazedoxifene.Investigational
NepafenacNepafenac may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
Niflumic AcidNiflumic Acid may increase the thrombogenic activities of Bazedoxifene.Approved
NimesulideNimesulide may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational, Withdrawn
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Bazedoxifene.Investigational
OspemifeneThe risk or severity of adverse effects can be increased when Bazedoxifene is combined with Ospemifene.Approved, Investigational
OtamixabanBazedoxifene may decrease the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the thrombogenic activities of Bazedoxifene.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Bazedoxifene.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Bazedoxifene.Approved
Pentaerythritol TetranitrateBazedoxifene may decrease the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateBazedoxifene may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PhenindioneBazedoxifene may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Bazedoxifene can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenprocoumonBazedoxifene may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the thrombogenic activities of Bazedoxifene.Approved, Vet Approved
PhenytoinThe serum concentration of Bazedoxifene can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PiroxicamPiroxicam may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
PomalidomidePomalidomide may increase the thrombogenic activities of Bazedoxifene.Approved
Potassium CitrateBazedoxifene may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Bazedoxifene.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Bazedoxifene.Investigational
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Bazedoxifene.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Bazedoxifene.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Bazedoxifene.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Bazedoxifene.Approved, Experimental, Investigational
PrimidoneThe serum concentration of Bazedoxifene can be decreased when it is combined with Primidone.Approved, Vet Approved
Protein CBazedoxifene may decrease the anticoagulant activities of Protein C.Approved
Protein S humanBazedoxifene may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBazedoxifene may decrease the anticoagulant activities of Protocatechualdehyde.Approved
ResveratrolResveratrol may increase the thrombogenic activities of Bazedoxifene.Approved, Experimental, Investigational
ReviparinBazedoxifene may decrease the anticoagulant activities of Reviparin.Approved, Investigational
RifampicinThe serum concentration of Bazedoxifene can be decreased when it is combined with Rifampicin.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Bazedoxifene.Approved
RivaroxabanBazedoxifene may decrease the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational, Withdrawn
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Bazedoxifene.Approved, Investigational
Salicylic acidSalicylic acid may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the thrombogenic activities of Bazedoxifene.Approved
SeliciclibSeliciclib may increase the thrombogenic activities of Bazedoxifene.Investigational
Sodium CitrateBazedoxifene may decrease the anticoagulant activities of Sodium Citrate.Approved, Investigational
SomatotropinThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Bazedoxifene.Approved, Investigational
SulfasalazineSulfasalazine may increase the thrombogenic activities of Bazedoxifene.Approved
SulindacSulindac may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
SulodexideBazedoxifene may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the thrombogenic activities of Bazedoxifene.Approved, Withdrawn
TalniflumateTalniflumate may increase the thrombogenic activities of Bazedoxifene.Approved
TenoxicamTenoxicam may increase the thrombogenic activities of Bazedoxifene.Approved
ThalidomideBazedoxifene may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Bazedoxifene.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Bazedoxifene.Approved
Tiaprofenic acidTiaprofenic acid may increase the thrombogenic activities of Bazedoxifene.Approved
TipranavirBazedoxifene may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Bazedoxifene.Approved, Withdrawn
TolmetinTolmetin may increase the thrombogenic activities of Bazedoxifene.Approved
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Bazedoxifene.Approved, Vet Approved
Trolamine salicylateTrolamine salicylate may increase the thrombogenic activities of Bazedoxifene.Approved
TroxerutinBazedoxifene may decrease the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Bazedoxifene.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Bazedoxifene.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational, Withdrawn
Vitamin CThe serum concentration of Bazedoxifene can be increased when it is combined with Vitamin C.Approved, Nutraceutical
WarfarinBazedoxifene may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranBazedoxifene may decrease the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
  1. Gruber C, Gruber D: Bazedoxifene (Wyeth). Curr Opin Investig Drugs. 2004 Oct;5(10):1086-93. [PubMed:15535430]
  2. Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD: Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008 Apr;23(4):525-35. [PubMed:18072873]
External Links
KEGG Drug
D03062
PubChem Compound
154257
PubChem Substance
310264867
ChemSpider
135921
BindingDB
50099585
ChEBI
135947
ChEMBL
CHEMBL46740
HET
29S
Drugs.com
Drugs.com Drug Page
Wikipedia
Bazedoxifene
ATC Codes
G03CC07 — Conjugated estrogens and bazedoxifeneG03XC02 — Bazedoxifene
PDB Entries
4xi3
FDA label
Download (671 KB)
MSDS
Download (58.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedPreventionMenopause1
1Active Not RecruitingTreatmentHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedOtherBone destruction2
1CompletedPreventionOne to five years postmenopausal1
1CompletedTreatmentMenopause2
1CompletedTreatmentOne to five years postmenopausal1
1Enrolling by InvitationTreatmentHealthy Volunteers1
1TerminatedBasic ScienceHealthy Volunteers1
1, 2RecruitingTreatmentBreast Cancer Metastatic / Metastatic Invasive Breast Cancer / Unresectable Locally Advanced Invasive Breast Cancer1
2CompletedNot AvailablePostmenopausal Osteoporosis (PMO)1
2RecruitingPreventionCancer, Breast1
2RecruitingTreatmentDisseminated Sclerosis / Menopause1
3CompletedPreventionBone destruction1
3CompletedTreatmentBone destruction / Menopause1
3CompletedTreatmentBone destruction1
4Active Not RecruitingPreventionRheumatoid Arthritis1
4CompletedNot AvailablePostmenopausal Osteoporosis (PMO)1
4RecruitingPreventionBMI >30 kg/m2 / Glucose Homeostasis / Postmenopausal Syndrome1
Not AvailableActive Not RecruitingNot AvailablePostmenopausal Osteoporosis (PMO)1
Not AvailableCompletedNot AvailableBone destruction2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral
Tablet, multilayer, extended releaseOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5998402No1997-04-042017-04-04Us
US6479535No1999-05-062019-05-06Us
US7138392No1997-04-042017-04-04Us
US7683051No2007-03-102027-03-10Us
US8815934No1999-05-062019-05-06Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000564 mg/mLALOGPS
logP6.03ALOGPS
logP6.01ChemAxon
logS-5.9ALOGPS
pKa (Strongest Acidic)9.63ChemAxon
pKa (Strongest Basic)9.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.86 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity141.9 m3·mol-1ChemAxon
Polarizability54.06 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 2-phenylindoles. These are indoles substituted at the 2-position with a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indoles
Direct Parent
2-phenylindoles
Alternative Parents
Phenylpyrroles / N-alkylindoles / Hydroxyindoles / 3-methylindoles / Phenoxy compounds / Phenol ethers / Azepanes / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Heteroaromatic compounds
show 4 more
Substituents
2-phenylindole / 2-phenylpyrrole / 3-alkylindole / Hydroxyindole / N-alkylindole / 3-methylindole / Phenoxy compound / Phenol ether / Phenol / 1-hydroxy-2-unsubstituted benzenoid
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Gruber C, Gruber D: Bazedoxifene (Wyeth). Curr Opin Investig Drugs. 2004 Oct;5(10):1086-93. [PubMed:15535430]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent m...
Gene Name
ESR2
Uniprot ID
Q92731
Uniprot Name
Estrogen receptor beta
Molecular Weight
59215.765 Da
References
  1. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR: Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005 Sep;146(9):3999-4008. Epub 2005 Jun 16. [PubMed:15961563]

Enzymes

1. UDP-glucuronosyltransferase 1A1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
References
  1. Lusin TT, Mrhar A, Trontelj J: UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene. Pharmazie. 2015 Feb;70(2):94-6. [PubMed:25997248]

Drug created on March 19, 2008 10:29 / Updated on June 02, 2018 09:37